Herbal supplements and therapeutic drug monitoring: Focus on digoxin immunoassays and interactions with St. John's Wort

Therapeutic Drug Monitoring

Volumn 30, Issue 2, 2008, Pages 212-217

  Dasgupta, Amitava ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Drug herb interactions; Herbal supplements; Immunoassays; St. Johns wort; Therapeutic drug monitoring

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ATAZANAVIR; CYCLOSPORIN; DIGITOXIN; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; FEXOFENADINE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INDINAVIR; IRINOTECAN; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; MIDAZOLAM; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PHENOBARBITAL; PHENPROCOUMON; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TACROLIMUS; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

AREA UNDER THE CURVE; AYURVEDA; CARDIOTOXICITY; CHAN SU; CHEMICAL COMPOSITION; CHINESE MEDICINE; CONFERENCE PAPER; CONTAMINATION; CROSS REACTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG MONITORING; DRUG OVERDOSE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GINSENG; HERB DRUG INTERACTION; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERICUM PERFORATUM; IMMUNOASSAY; INTOXICATION; LIQUID CHROMATOGRAPHY; LU SHEN WAN; MASS SPECTROMETRY; MICROPARTICLE ENZYME IMMUNOASSAY; NONHUMAN; OLEANDER; PRIORITY JOURNAL; SALVIA MILTIORRHIZA; SINGLE DRUG DOSE; SUPPLEMENTATION; TREATMENT FAILURE; WITHANIA SOMNIFERA;

DIGOXIN; DRUG CONTAMINATION; DRUG MONITORING; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; IMMUNOASSAY; PHYTOTHERAPY; PLANT EXTRACTS; PLANT PREPARATIONS;

EID: 42049088061     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31816b918f     Document Type: Conference Paper

References (48)

1. Gulla J, Singer AJ, Gaspari R. Herbal use in ED patients. Acad Emerg Med. 2001;8:450.
2. Mahady GB. Global harmonization of herbal health claims. J Nutr. 2001;131:1120S-1123S.
3. Fushimi R, Amino N. Digoxin concentration in blood [in Japanese; abstract in English]. Rinsho Byori. 1995;43:34-40.
4. Panesar NS. Bufalin and unidentified substances in traditional Chinese medicine cross react in commercial digoxin assay. Clin Chem. 1992;38:2155-2156.
5. Ko R, Greenwald M, Loscutoff S, et al. Lethal ingestion of Chinese tea containing Chan Su. Western J Med. 1996:164;71-75.
6. Dasgupta A, Biddle D,Wells A, et al. Positive and negative interference of Chinese medicine Chan Su in serum digoxin measurement: elimination of interference by using a monoclonal chemiluminescent digoxin assay or monitoring free digoxin concentration. Am J Clin Pathol. 2000;114:174-179.
7. Valdes R Jr, Jortani SA. Unexpected suppression of immunoassay results by cross-reactivity: now a demonstrated cause of concern. Clin Chem. 2002;48:406-406.
8. Eddleston M,Warrell DA. Management of yellowoleander poisoning. Q J Med. 1999;92:483-485.
9. Eddleston M, Ariaratnam CA, Meyer PW, et al. Epidemic of self poisoning with seeds of oleander tree (Thevetia peruviana) in north Sri Lanka. Trop Med Int Health. 1999;4:266-273.
10. Cheung K, Hinds JA, Duffy P. Detection of poisoning by plant origin cardiac glycosides with the Abbott TDx analyzer. Clin Chem. 1989;35:295-297.
11. Osterloh J. Cross-reactivity of oleander glycosides [letter]. J Anal Toxicol. 1988;12:53.
12. Eddleston M, Ariaratnam CA, Sjostrom L, et al. Acute yellow oleander (Thevetia peruvica) poisoning: cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to hospital. Heart. 2000;83:310-306.
13. Dasgupta A, Datta P. Rapid detection of oleander poisoning by using digoxin immunoassays: comparison of five assays. Ther Drug Monit. 2004;26:658-663.
14. Wahed A, Dasgupta A. Positive and negative in vitro interference of Chinese medicine Dan Shen in serum digoxin measurement: elimination of interference by monitoring free digoxin concentration. Am J Clin Pathol. 2001;116:403-408.
15. McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ. 1996;155:293-295.
16. Dasgupta A, Wu S, Actor J, et al. Effect of Asian and Siberian ginseng on serum digoxin measurement by five digoxin immunoassays: significant variation in digoxin-like immunoreactivity among commercial ginsengs. Am J Clin Pathol. 2003;119:298-303.
17. Shumanik GM, Wu AW, Ping AC. Oleander poisoning: treatment with digoxin-specific Fab antibody fragments. Ann Emerg Med. 1988;17:732-735.
18. Zylber-Katz E, Safadi R, Kevy I, et al. Digoxin specific fab fragment in the treatment of oleander poisoning in man [abstract]. Ther Drug Monit. 1995;17:419.
19. Dasgupta A, Szelei-Stevens K. Neutralization of free digoxin-like immunoreactive components of Oriental medicines Dan Shen and Lu-Shen-Wan by the fab fragment of anti-digoxin antibody (Digibind). Am J Clin Pathol. 2004;121:276-281.
20. Corns CM. Herbal remedies and clinical biochemistry. Ann Clin Biochem. 2003;40:489-507.
21. Lau KK, Lai CK, Chan AW. Phenytoin poisoning after using Chinese proprietary medicines. Hum Exp Toxicol. 2000;19:385-386.
22. Skoulidis F, Alexander GJ, Davies SE. Ma huang associated acute liver failure requiring liver transplantation. Eur J Gastroenterol Hepatol. 2005;17:581-584.
23. Saper RB, Kales SN, Paquin J, et al. Heavy metal content of ayurvedic herbal medicine products. JAMA. 2004;292:2868-2873.
24. Amster E, Tiwary A, Schenker MB. Case report: potential arsenic toxicosis secondary to herbal kelp supplement. Environ Health Prespect. 2007;115:606-608.
25. Venkataraman R, Komoroski B, Strom S. In vitro and in vivo assessment of herb-drug interactions. Life Sci. 2006;78:2105-2115.
26. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs. 2005;65:1239-1282.
27. Williamson EM. Interactions between herbal and conventional medicines. Expert Opin Drug Safety. 2005;4:355-378.
28. Marchetti S, Mazzanti R, Beijnen JH, et al. Concise review: clinical significance of drug-drug and herb interactions mediated by ABC transporter ABCB1 (MDR1 p-glycoprotein). Oncologists. 2007;12:927-941.
29. Charrios TL, Sadler C, Vohra S. Complementary, holistic and integrative medicine: St. John's wort. Pediatr Rev. 2007;28:69-72.
30. Holstege CP, Mitchell K, Barlotta K, et al. Toxicity and drug interactions associated with herbal products: ephedra and St. John's wort. Med Clin North Am. 2005;89:1225-1257.
31. Madabushi R, Frank B, Drewlow B, et al. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol. 2006;62:225-233.
32. Wentworth JM, Agostini M, Love J, et al. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol. 2000;166:R11-R16.
33. Dasgupta A, Tso G, Szelei-Stevens K. St. John's wort does not interact with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays. J Clin Lab Anal. 2006;20:62-67.
34. Barone GW, Gurley BJ, Ketel BL, et al. Herbal supplements, a potential for drug interactions in transplant recipients. Transplantation. 2001;71:239-241.
35. van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, et al. Possible drug metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev. 2006;38:477-514.
36. Nebel A, Schneider BJ, Kroll DJ. Potential metabolic interaction between St. John's Wort and theophylline. Ann Pharmacother. 1999;33:502.
37. Morimoto T, Kotegawa T, Tsutsumi K, et al. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol. 2004;44:95-101.
38. Muller SC, Uehleke B, Woehling H, et al. Effect of St. John's wort dose and preparation on the pharmacokinetics of digoxin. Clin Pharmacol Ther. 2004;75:546-557.
39. Tannergren C, Engman H, Knutson L, et al. St. John's wort decreases bioavailability of R and S verapamil through induction of fast pass metabolism. Clin Pharmacol Ther. 2004;75:298-309.
40. Johne A, Schmider J, Brockmoller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol. 2002;22:46-54.
41. Niederhofer H. St. John's wort may diminish methylphenidate's efficacy in treating patients suffering from attention deficit hyperactive disorder. Med Hypothesis. 2007;68:1189.
42. Andren L, Andreasson A, Eggertsen R. Interaction between commercially available St. John's wort products (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol. 2007;63:913-916.
43. Draves AH, Walker SE. Analysis of hypericin and pseudohypericin content of commercially available St. John's wort preparation. Can J Clin Pharmacol. 2003;10:114-118.
44. Arold G, Donath F, Maurer A, et al. No relevant interaction with alprazolam, caffeine, tolbutamide and digoxin by treatment with a low hyperforin St. John's wort extract. Planta Med. 2005;71:331-337.
45. Ang CY, Hu L, Heinze TM, et al. Instability of St. John's wort (Hypercium perforatum L) and degradation of hyperforin in aqueous solutions and functional beverage. J Agric Food Chem. 2004;52:6156-6164.
46. Burstein AH, Hortan RL, Dunn T, et al. Lack of effect of St. John's wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2000;68:605-612.
47. Bell EC, Ravis WR, Chan HM, et al. Lack of pharmacokinetic interaction between St. John's wort and prednisone. Ann Pharmacother. 2007;41:1819-1924.
48. Dasgupta A, Hovanetz M, Olsen M, et al. Drug-herb interaction: effect of St. John's wort on bioavailability and metabolism of procainamide in mice. Arch Pathol Lab Med. 2007;131:1094-1098.